Co-Diagnostics Files Initial Annual Report on Form 10-K and Updates Corporate Developments

CODX updates on initial six months as a public company SALT LAKE CITY (BUSINESS WIRE) Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the filing of its initial Annual Report on Form 10-K as a public company. Co-Diagnostics completed its initial public offering (“IPO”) on July 17, 2017. 2017 Financial Results: Revenue for the year totaled $7,700, primarily licensing revenue, compared to zero revenue in full year 2016. Deferred income The post Co-Diagnostics Files Initial Annual Report on Form 10-K and Updates Corporate Developments appeared first on Public Wire.
http://bit.ly/2EmbWEC